Advertisement

Managing Osteoporosis in Oldest of Old

  • Vasi NaganathanEmail author
  • Kujan Nagaratnam
Chapter

Abstract

Older people are at high risk of fracture because of osteoporosis and falls. Fractures in older people are responsible for significant morbidity, mortality and loss of independence. Preventing and managing osteoporosis can reduce the risk of future fracture which in turn prevents potential deterioration in quality of life. Older people should be assessed for their risk of future fracture. Risk factors for osteoporosis and causes for low bone density should be identified. Measuring bone density helps in assessing risk of future fracture. Osteoporosis treatment is aimed at reducing risk of future fracture by improving bone mass and bone strength or preventing loss of bone mass and strength. Treatment options in older people include calcium supplements, vitamin D supplements, bisphosphonates and denosumab.

Keywords

Osteoporosis – oldest old Osteoporotic fractures – bone mineral density 

References

  1. 1.
    Heaney RP. Pathophysiology of osteoporosis. Endocrinol Metab Clin N Am. 1998;27(2):255–65.CrossRefGoogle Scholar
  2. 2.
    Crischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med. 1991;151:2026–32.CrossRefGoogle Scholar
  3. 3.
    Iqbal MM. Osteoporosis: epidemiology, diagnosis and treatment. Medscape. http://www.medscape.com/viewarticle/410461_3. Retrieved 24 Feb 2015.
  4. 4.
    Davison KS, Kendler DL, Ammann P, Bauer DC, Dempster DW, Dian L, et al. Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond. Am J Med. 2009;122(11):992–7.CrossRefGoogle Scholar
  5. 5.
    Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E. FRAX and its applications to clinical practice. Bone. 2009;44(5):734–43. http://www.sheffield.ac.uk/FRAX/.CrossRefGoogle Scholar
  6. 6.
    Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int. 2008;19(10):1431–44. https://www.garvan.org.au/promotions/bone-fracture-risk/calculator/.CrossRefGoogle Scholar
  7. 7.
    Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22(4):477–501.CrossRefGoogle Scholar
  8. 8.
    Trived DP, Doll R, Kahm KT. Effect of four months oral vitamin D3 (cholecalciferol) supplement in fractures and mobility in men and women living in the community: randomized double-blind controlled trial. BMJ. 2003;326:468.CrossRefGoogle Scholar
  9. 9.
    Zhao JG, Zeng XT, Wang J, Liu L. Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: a systematic review and meta-analysis. JAMA. 2017;318(24):2466–82.CrossRefGoogle Scholar
  10. 10.
    Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007;370(9588):657–66.CrossRefGoogle Scholar
  11. 11.
    Bischoff-Ferrari HA, Willett WC, Wong JB, Stuck AE, Staehelin HB, Orav EJ, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009;169(6):551–61.CrossRefGoogle Scholar
  12. 12.
    Group D. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ. 2010;340:b5463.CrossRefGoogle Scholar
  13. 13.
    Bergman GJ, Fan T, McFetridge JT, Sen SS. Efficacy of vitamin D3 supplementation in preventing fractures in elderly women: a meta-analysis. Curr Med Res Opin. 2010;26(5):1193–201.CrossRefGoogle Scholar
  14. 14.
    Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med. 1992;327(23):1637–42.CrossRefGoogle Scholar
  15. 15.
    Masud T, McClung M, Geusens P. Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. Clin Interv Aging. 2009;4:445–9.CrossRefGoogle Scholar
  16. 16.
    Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799–809.CrossRefGoogle Scholar
  17. 17.
    Arrain Y, Masud T. A current update on osteonecrosis of the jaw and bisphosphonates. Dental Update. 2011;38(10):672–6.CrossRefGoogle Scholar
  18. 18.
    McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GL, Moffet AH, et al. Denosumab in postmenopausal women with low bone mineral density. NEJM. 2006;354:81–91.CrossRefGoogle Scholar
  19. 19.
    Burkiewicz JS, Scarpace SL, Bruce ST. Denosumab in osteoporosis and oncology. Ann Pharmacother. 2009;43(9):1445–55. doi:  https://doi.org/10.1345/aph.1M102. Epub 2009 Jul 21.CrossRefGoogle Scholar
  20. 20.
    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.CrossRefGoogle Scholar
  21. 21.
    Ebeling PR. Strategies for the treatment of osteoporosis. Aust Prescr. 2011;34:176–81.CrossRefGoogle Scholar
  22. 22.
    Gambacciani M, Levancini M. Management of postmenopausal osteoporosis and prevention of fractures. Panminerva Med. 2014;56(2):115–31.PubMedGoogle Scholar
  23. 23.
    Reid IR. Editorial. Controversies in osteoporosis management. Intern Med J. 2016;47(7):767–70.CrossRefGoogle Scholar
  24. 24.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41.CrossRefGoogle Scholar
  25. 25.
    Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med. 2007;146(5):326–39.CrossRefGoogle Scholar
  26. 26.
    Raloxifene Hydrochloride. Australian Prescriber. 1999;22:95.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Centre for Education and Research on Ageing, Faculty of Medicine and HealthThe University of Sydney and Ageing and Alzhiemer’s Institute, Concord HospitalSydneyAustralia
  2. 2.Sydney Medical SchoolThe University of SydneySydneyAustralia

Personalised recommendations